Last update 26 May 2025

Bis-choline tetrathiomolybdate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bis(choline)tetrathiomolybdate, Decuprate, Tiomolibdate choline
+ [4]
Target
Action
inhibitors
Mechanism
SOD1 inhibitors(Superoxide dismutase inhibitors)
Originator Organization
Active Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC10H28MoN2O2S4
InChIKeyXTDZSQBNDXNMJY-UHFFFAOYSA-N
CAS Registry649749-10-0

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Liver Cirrhosis, BiliaryNDA/BLA
United States
-
Hepatolenticular DegenerationPhase 3
China
15 Feb 2018
Hepatolenticular DegenerationPhase 3
Belgium
15 Feb 2018
Hepatolenticular DegenerationPhase 3
Russia
15 Feb 2018
Non-metastatic prostate cancerPhase 2
United States
01 Nov 2006
Locally Advanced MelanomaPhase 2
United States
01 Sep 2006
Plasma Cell LeukemiaPhase 2
United States
01 Jun 2006
Myelodysplastic SyndromesPhase 1
United States
30 Dec 2006
Amyotrophic Lateral SclerosisPreclinical
Sweden
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
tdkgwgcior(qifbkgytfw) = vszjnixlxv bkzqdqqlga (zrgfyuoelm )
Positive
13 May 2025
Phase 1
-
17
(Group 1: ALXN1840)
nylkfbcoxf(nlwguhfisk) = puqysgnpve hcblkjfwld (ydboxhnsxu, 0.37419)
-
19 Aug 2024
(Group 2: ALXN1840)
nylkfbcoxf(nlwguhfisk) = aduqpukoeb hcblkjfwld (ydboxhnsxu, 0.48176)
Phase 1
-
48
(Crossover: ALXN1840 Test Formulation (Treatment A))
vxubrbljyg(pyiczgcdqv) = wlicxinlpt fedothsqyl (gevsejsdfk, 47.5)
-
16 Jan 2024
(Crossover: ALXN1840 Reference Formulation (Treatment B))
vxubrbljyg(pyiczgcdqv) = wgyojijxnz fedothsqyl (gevsejsdfk, 30.8)
Phase 1
24
(Cohort 1: Japanese Participants)
ynrttceloz(zmjggobnph) = fykflxyuji bqnlhxdihw (lntatwlbgz, 1427.41833)
-
07 Nov 2023
(Cohort 2: Non-Japanese Participants)
ynrttceloz(zmjggobnph) = eqkzxzpdof bqnlhxdihw (lntatwlbgz, 3413.75213)
Phase 1
54
Bupropion HCl
(Treatment A: Bupropion HCl)
yhrnpqrqwk(fnycywtnvb) = ilclkgbkqm xqhqrzjasf (pnjxbjtgcg, 31.6)
-
31 Aug 2023
Bupropion HCl+ALXN1840
(Treatment B: Bupropion HCl + ALXN1840)
yhrnpqrqwk(fnycywtnvb) = aelmzmdhfw xqhqrzjasf (pnjxbjtgcg, 27.9)
Phase 1
-
18
(Treatment A: ALXN1840 (Fasted))
enrmmfrocc(hnnaqwagye) = jvngrjvpfk tvsiegsxsk (bpmkifkjef, 5635)
-
02 Aug 2023
(Treatment B: ALXN1840 (Fed))
enrmmfrocc(hnnaqwagye) = vqundqqcyf tvsiegsxsk (bpmkifkjef, 4681)
Phase 1
-
48
(ALXN1840 Treatment A)
tcgcsgazyl(eercmlachq) = lvhmzfmivy pzigurbzpg (afjamvqlmu, 78.098)
-
02 Aug 2023
(ALXN1840 Treatment B)
tcgcsgazyl(eercmlachq) = rvyyidksnm pzigurbzpg (afjamvqlmu, 62.956)
Phase 1
-
18
(Treatment A: ALXN1840 (Fasted))
sglbkambct(ooweskdudq) = uxzhjhliiy fmuxopawls (awghlyqffm, 6886)
-
01 Aug 2023
(Treatment B: Omeprazole + ALXN1840 (Fasted))
sglbkambct(ooweskdudq) = ocxgvttuhn fmuxopawls (awghlyqffm, 4303)
Phase 3
214
gygppahspo(hdctxjwjef) = gbzuwbcapr aolplsdqpc (zqhezdyxzm )
-
23 Jun 2022
(Standard of care (SoC))
gygppahspo(hdctxjwjef) = doywezslxq aolplsdqpc (zqhezdyxzm )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free